The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Saved in:
| Title: | The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. |
|---|---|
| Authors: | Ochman AR; Melior Discovery, Inc., 860 Springdale Dr., Exton, PA 19341, USA., Lipinski CA, Handler JA, Reaume AG, Saporito MS |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2012 Jul; Vol. 342 (1), pp. 23-32. Date of Electronic Publication: 2012 Mar 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 22431203 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ochman+AR%22">Ochman AR</searchLink>; Melior Discovery, Inc., 860 Springdale Dr., Exton, PA 19341, USA.<br /><searchLink fieldCode="AU" term="%22Lipinski+CA%22">Lipinski CA</searchLink><br /><searchLink fieldCode="AU" term="%22Handler+JA%22">Handler JA</searchLink><br /><searchLink fieldCode="AU" term="%22Reaume+AG%22">Reaume AG</searchLink><br /><searchLink fieldCode="AU" term="%22Saporito+MS%22">Saporito MS</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220376362%22">The Journal of pharmacology and experimental therapeutics</searchLink> [J Pharmacol Exp Ther] 2012 Jul; Vol. 342 (1), pp. 23-32. <i>Date of Electronic Publication: </i>2012 Mar 19. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>0376362 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1521-0103 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200223565%22">00223565 </searchLink><i>NLM ISO Abbreviation: </i>J Pharmacol Exp Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=22431203 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1124/jpet.112.192187 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 23 Titles: – TitleFull: The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ochman AR – PersonEntity: Name: NameFull: Lipinski CA – PersonEntity: Name: NameFull: Handler JA – PersonEntity: Name: NameFull: Reaume AG – PersonEntity: Name: NameFull: Saporito MS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2012 Jul Type: published Y: 2012 Identifiers: – Type: issn-electronic Value: 1521-0103 Numbering: – Type: volume Value: 342 – Type: issue Value: 1 Titles: – TitleFull: The Journal of pharmacology and experimental therapeutics Type: main |
| ResultId | 1 |
